Now Approved: APHEXDA™ (motixafortide) for injection – 9/12/2023

NOW APROVED: APHEXDATM (motixafortide) for injection

APHEXDA™ is indicated in combination with

filgrastim (G-CSF) to mobilize

hematopoietic stem cells to the peripheral blood for

collection and subsequent autologous transplantation in

patients with multiple myeloma.

APHEXDATM (motixafortide) for injection, for subcutaneous use

U.S. Approval: 2023


Dosing Form and Strength

WAC Pricing


For Injection: 62 mg as a lyophilized powder in a single-dose vial for reconstitution

$5900 per vial



APHEXDA is contraindicated in patients with a history of serious hypersensitivity reactions to motixafortide.


  • Anaphylactic Shock and Hypersensitivity Reactions: Anaphylactic shock and hypersensitivity reactions have occurred. Premedicate all patients with a triple drug premedication regimen that includes an H1-antihistamine, an H2 blocker, and a leukotriene inhibitor approximately 30-60 minutes prior to each dose of APHEXDA. Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following APHEXDA administration and manage reactions promptly. Patients receiving negative chronotropic drugs (e.g., beta-blockers) may be more at risk for hypotension in the event of a hypersensitivity reaction and these drugs, when appropriate, should be replaced with non-chronotropic drugs.

  • Injection Site Reactions: Injection site reactions (73%) including pain (53%), erythema (27%), and pruritus (24%) have occurred. Severe reactions occurred in 9% of patients. Premedicate with an analgesic premedication (e.g., acetaminophen) prior to each APHEXDA dose. Use analgesic medication and local treatments post-dose, as needed.

  • Tumor Cell Mobilization in Patients with Leukemia: For the purpose of hematopoietic stem cell (HSC) mobilization, APHEXDA may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, APHEXDA is not intended for HSC mobilization and harvest in patients with leukemia.

  • Leukocytosis: Administering APHEXDA in conjunction with filgrastim increases circulating leukocytes as well as HSC populations. Monitor white blood cell counts during APHEXDA use.

  • Potential for Tumor Cell Mobilization: When APHEXDA is used in combination with filgrastim for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.

  • Embryo-fetal Toxicity: Based on its mechanism of action, APHEXDA can cause fetal harm. Advise pregnant women of the potential risk to the fetus. Verify pregnancy status in females of reproductive potential prior to initiating treatment with APHEXDA and advise use of effective contraception during treatment and for 8 days after the final dose.



The most common adverse reactions (incidence >20%) in patients treated with APHEXDA were injection site reactions [73%, including pain (53%), erythema (27%), pruritis (24%)]; pruritus (38%); flushing (33%); back pain (21%).


Pregnancy: Please see the important information in Warnings and Precautions under Embryo-fetal Toxicity.

Lactation: There are no data on the presence of motixafortide in human milk, the effects on the breastfed child, or the effects on milk production. Advise females that breastfeeding is not recommended during treatment with APHEXDA and for 8 days after the final dose.

Pediatric Use: The safety and effectiveness of APHEXDA have not been established in pediatric patients.

Please see the accompanying full Prescribing Information

To report SUSPECTED ADVERSE REACTIONS, contact BioLineRx at 1-800-574-9978 or FDA at 1-800-FDA-1088 or

©2023 BioLineRx USA, Inc. All rights reserved.

APHEXDA™ is a trademark owned or licensed by BioLineRx Ltd., its subsidiaries, or affiliates.

APHEXDA is available by prescription only.

US-APH-2300048 (v 1.0) 09/2023